Large-scale mass tort coalitions are fundamentally changing litigation strategy by consolidating plaintiff power through formal steering committees and national counsel networks, enabling settlements at unprecedented scale while shifting control away from individual attorneys and toward coordinated groups that negotiate as unified entities. Where litigation once proceeded fragmented across multiple jurisdictions with competing attorney interests, today’s coalitions operate with centralized decision-making structures that compress negotiation timelines and increase settlement values. The GSK Zantac settlement, which consolidated 80,000 lawsuits and generated a $2.2 billion recovery negotiated by just 10 major plaintiffs’ law firms, illustrates this transformation—a settlement structure that would have been nearly impossible to execute 15 years ago when thousands of individual plaintiff attorneys each controlled their own cases. This shift reflects both the economics and the complexity of modern mass tort litigation.
The 158 active MDL (Multidistrict Litigation) dockets now pending across the U.S. contain 197,965 cases, with the 25 largest MDLs accounting for 95.2% of all pending claims. The concentrated power held by a handful of law firms on each Plaintiff Steering Committee (PSC) has become the dominant force shaping how damages are calculated, how liability is evaluated, and ultimately what settlements look like. This centralization has advantages for efficiency but also raises questions about whether individual claimants receive adequate representation or whether the system now favors rapid resolution over maximum individual recovery.
Table of Contents
- How Plaintiff Steering Committees Control Modern Coalition Strategy
- The Economic Pressure Behind Coalition Formation and Consolidation
- Emergence of New Coalition Tactics: Speed vs. Proof
- Marketing Spend as a Strategic Coalition Weapon
- The Constraint of Court-Mandated Causation Rigor
- Emerging Litigation Frontiers Reshaping Coalition Strategy
- The Concentration of Settlement Power and Its Consequences
How Plaintiff Steering Committees Control Modern Coalition Strategy
Plaintiff Steering Committees, appointed or elected by federal judges to represent coalition interests in formally consolidated MDLs, have become the de facto government of mass tort litigation. These committees typically include 5–15 attorneys representing the largest plaintiff firms, and they control discovery, expert selection, trial strategy, and settlement authority. The committee structure eliminates the chaos of thousands of independent attorneys pursuing conflicting strategies, but it also concentrates enormous power in a small number of hands. The lead counsel on a PSC can shape the entire direction of a case—deciding which experts to hire, which causation theories to pursue, and at what point settlement becomes preferable to continued litigation.
The national counsel model extends this power beyond the MDL itself. Large defense firms and increasingly large plaintiff firms now maintain standing relationships with local counsel in virtually every U.S. state, enabling coordinated mass tort defense or plaintiff strategies that span multiple jurisdictions simultaneously. This creates asymmetrical power dynamics: a well-funded plaintiff coalition with established national counsel relationships can pressure smaller, locally-based defendants far more effectively than fragmented individual attorneys ever could. However, this concentration also means that attorneys without a seat at the PSC table—often solo or small-firm practitioners—have minimal influence over strategy and may receive smaller fee arrangements or even be excluded from settlements altogether.
The Economic Pressure Behind Coalition Formation and Consolidation
Modern mass tort coalitions exist partly because the cost of litigation has become unsustainable for individual firms. A single pharmaceutical mass tort case now requires experts in pharmacology, epidemiology, toxicology, and biostatistics—specialists who cost $10,000–$50,000 per engagement. Depositions in complex product liability cases routinely span weeks. Discovery can generate millions of documents. No solo practitioner can afford this alone, so they must either join a coalition or abandon the case entirely.
This economic reality has compressed the plaintiff bar into an oligopoly where a handful of well-capitalized firms—names like Motley Rice, Lieff Cabraser, Milberg, and a few others—dominate the space. The GSK Zantac case exemplifies this. The settlement involved 80,000 lawsuits but was negotiated by only 10 law firms. The remaining thousands of plaintiffs’ attorneys who had filed Zantac cases had to either accept the PSC’s negotiated settlement or opt out and pursue individual claims—a costly gamble. Most chose to accept the PSC deal, even if it meant smaller fees or less favorable recovery terms, because the alternative was spending years litigating alone against a massive corporation. This dynamic incentivizes rapid coalition formation and discourages holdouts, but it also creates situations where smaller or less-resourced attorneys effectively lose control over their clients’ cases.
Emergence of New Coalition Tactics: Speed vs. Proof
As coalitions have matured, they’ve developed new tactical approaches that prioritize settlement speed over prolonged litigation. The current litigation environment shows marked shifts in strategy: MDL filings dropped dramatically from 75,570 cases in 2024 to 37,735 cases in 2025, suggesting that either plaintiffs are filing with more selective case criteria or that coalitions are pushing cases toward settlement faster. Courts have responded by demanding clearer causation proof and stronger expert medical opinions, making the traditional strategy of overwhelming the defense with case volume less viable. This has forced coalitions to become more selective about which claims they pursue and more rigorous in the quality of evidence they present. The GLP-1/Ozempic litigation demonstrates this shift.
GLP-1 mass tort cases surged 130% year-over-year to reach 3,191+ pending cases in 2025, driven by claims of gastrointestinal obstruction and gallbladder injury. Unlike older litigation areas where causation was sometimes ambiguous, Ozempic claims rest on relatively straightforward pharmacological mechanisms—the drug is known to slow gastric motility, which can cause obstruction in susceptible individuals. Coalitions pursuing these cases can move faster because the science is simpler. However, this same clarity also means that defendants have fewer places to hide in discovery, which can accelerate both settlement negotiations and trial verdicts. The tradeoff is that coalitions in older, messier litigation areas (like talcum powder causation, which involves decades of epidemiological debate) must invest more heavily in expert testimony and may face longer litigation timelines.
Marketing Spend as a Strategic Coalition Weapon
Today’s coalitions wage what amounts to marketing warfare for claimants. Law firms now allocate millions of dollars on marketing initiatives to acquire plaintiffs, with costs escalating rapidly as competition intensifies between different coalition groups pursuing the same case category. This spending includes television advertising, digital marketing, SEO campaigns targeting symptom-based searches, and direct-to-consumer outreach. A coalition pursuing Ozempic cases may simultaneously advertise in multiple regions, potentially funding multiple marketing campaigns that compete against each other—inefficient but necessary to maintain market share.
This marketing-driven acquisition strategy has fundamentally changed coalition composition. Rather than coalitions forming around individual attorneys’ preexisting client relationships, modern coalitions often form around shared marketing budgets and client acquisition campaigns. A firm that can afford to spend $2 million per month on digital advertising can rapidly assemble thousands of claimants, giving them negotiating leverage that translates into PSC seats and fee arrangements. Smaller firms without this advertising capacity find themselves either funding marketing at unsustainable levels or joining coalitions and ceding control to better-capitalized competitors. The DePuy Orthopedics hip implant settlement ($2.5 billion for approximately 8,000 claims) was negotiated by firms that had collectively invested heavily in marketing to acquire those 8,000 clients—firms without that capital simply could not participate at the negotiating table.
The Constraint of Court-Mandated Causation Rigor
Despite coalitions’ strategic sophistication, they now face a significant constraint: courts are increasingly demanding stronger proof of causation before allowing cases to proceed or settle. This represents a fundamental shift from earlier mass tort litigation, where plaintiffs could sometimes win on epidemiological association alone. Modern courts now require more specific evidence linking individual exposure to individual injury, with independent medical causation for each claimant or at least a well-defined subgroup of claimants. This heightened scrutiny has forced coalitions to invest more heavily in medical screenings, individual case evaluation, and expert testimony—costs that eat into settlements and can delay resolution.
AFFF (aqueous film-forming foam) litigation, which grew 99% in 2025 and now involves 15.2K pending cases, illustrates this constraint. PFAS chemicals are known to persist in groundwater and have been linked to liver disease, kidney disease, thyroid disease, and other conditions in some studies, but the epidemiological evidence for any single individual is often ambiguous. Coalitions pursuing AFFF cases must now prove not just that PFAS exposure occurred but that it caused a specific documented injury in each claimant. This requires individual medical records review, exposure reconstruction, and expert testimony—all expensive and time-consuming. A coalition that once might have moved 1,000 cases toward settlement in a year now struggles to move 500 because of this heightened proof burden.
Emerging Litigation Frontiers Reshaping Coalition Strategy
The composition of active mass tort litigation is shifting. AI-related mass torts are expected to rise, including claims of misdiagnosis from AI health system failures—a category where causation will be even more complex than traditional medical device litigation. Social media addiction litigation is now actively consolidating, alleging that technology companies deliberately created psychologically manipulative features targeting adolescent users. These emerging areas are reshaping how coalitions form because the expertise required is different: AI and social media cases require technology experts, digital forensics specialists, and psychologists rather than traditional pharmaceutical epidemiologists.
J&J’s talcum powder litigation, which still carries 68,000 pending cases and represents the single largest active MDL by volume, is illustrative of how coalitions handle legacy litigation. These cases rest on epidemiological evidence and scientific causation theories that have been litigated for over 20 years. Coalitions pursuing talcum claims must navigate decades of prior discovery, conflicting expert opinions, and established legal precedents. Meanwhile, newer coalitions pursuing AFFF cases (15.2K pending) or AI-related claims are building strategy from scratch, with fewer constraints from prior rulings but also greater uncertainty about how courts will evaluate novel causation theories.
The Concentration of Settlement Power and Its Consequences
The most consequential change driven by mass tort coalitions is the concentration of settlement authority. A decade ago, settling a mass tort might require consensus from dozens or hundreds of plaintiff attorneys, each with veto power over their own clients’ claims. Today, a PSC representing 10–15 firms can bind tens of thousands of claimants to a settlement agreement, sometimes over objections from smaller attorneys or individual claimants who believe the deal is too low. This concentration accelerates settlement negotiations—GSK paid $2.2 billion to resolve Zantac through negotiations with just 10 firms—but it also means that the settlement value negotiated by committee may not reflect the true value that individual claimants might have received through trial or individual negotiation.
The J&J talcum powder MDL, with its 68,000 pending cases, exists precisely because coordinated coalition litigation proved more effective at generating large settlements than fragmented individual litigation ever could. However, the concentration of power also creates pressure toward settlement even when the evidence might support higher jury awards. A PSC facing the prospect of years more litigation, expert testimony costs, and discovery battles may rationally choose a $2–3 billion settlement even if plaintiffs might recover $5–10 billion through trial, because the time value of money, the risk of defense summary judgment, and the certainty of settlement all push toward early resolution. Individual claimants with strong cases may find themselves bound to a committee-negotiated settlement that undervalues their claims.